Opportunity Information: Apply for RFA HL 14 024
Apply for RFA HL 14 024
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233 National Center on Sleep Disorders Research 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jan 7, 2015 and posted on Oct 23, 2013.
- Applicants must submit their applications by Jan 8, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $499,999.00 in funding.
- Eligible applicants include: Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) County governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities City or township governments Independent school districts Small businesses Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity RFA-HL-14-024, titled "Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)," supports investigator-initiated basic science projects aimed at understanding why and how HIV contributes to diseases of the heart, lungs, and blood. The central focus is on fundamental mechanisms of pathogenesis, meaning applicants are expected to dig into underlying biology rather than primarily testing a clinical intervention or running a population-level outcomes study. A key feature of the announcement is that it explicitly welcomes studies of HIV-related HLB disease both in the absence of antiretroviral therapy and in the modern treatment era, recognizing that ART has reshaped HIV biology and patient risk profiles while not eliminating cardiovascular, pulmonary, and hematologic complications. The overall intent is to build the kind of rigorous mechanistic foundation that can later drive smarter therapeutic strategies for HIV-associated HLB conditions in both adults and children.
The FOA uses the R01 research project grant mechanism, which is the standard NIH vehicle for hypothesis-driven, multi-year research programs led by a principal investigator. Projects can use a wide range of experimental systems and approaches, including work in primary cell types and patient-derived biospecimens, as well as computational and other modeling strategies. The announcement also emphasizes the use of animal models, particularly those commonly used in HIV research, which signals strong interest in mechanistic studies that can connect viral factors, host responses, and treatment-related effects in a controlled system. In practical terms, this flexibility allows applicants to propose anything from molecular and cellular studies of HIV-driven inflammation and immune dysregulation affecting vascular or lung tissue, to systems-level modeling of pathways that may explain ART-era shifts in cardiopulmonary risk, to mechanistic hematology studies on coagulation, platelet function, anemia, or marrow effects in the context of chronic HIV infection and treatment.
From an administrative standpoint, this is a discretionary grant opportunity under NIH, aligned with multiple activity areas reflected in the CFDA listings: 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), 93.839 (Blood Diseases and Resources Research), and 93.233 (National Center on Sleep Disorders Research). The inclusion of these CFDA numbers indicates that the scientific scope is broad across heart, lung, and blood domains, and that applications may reasonably intersect with related physiological systems when relevant to HIV-associated HLB disease mechanisms. The opportunity does not require cost sharing or matching, which is consistent with most NIH R01 research funding.
The published award ceiling is listed as $499,999, which effectively sets expectations about the scale of direct costs that are likely to be considered under this announcement (while applicants should still follow the specific budget rules and NIH policy details in the full FOA). Key timeline information shows the FOA was posted on October 23, 2013, with an original closing date of January 8, 2015, and a final (current) closing date of January 8, 2016, after which it was archived on February 8, 2016. In other words, it was a time-limited solicitation rather than an open-ended standing program announcement.
Eligibility is broad across public and private sectors. Eligible applicants include state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status (with the usual NIH distinctions); small businesses; for-profit organizations other than small businesses; independent school districts; public housing authorities/Indian housing authorities; and a range of mission-driven and capacity-building institution types called out under NIH policy such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISIs. The FOA also notes that certain federal agencies and faith-based or community-based organizations may be eligible. A critical restriction is that non-U.S. entities (foreign institutions) are not eligible to apply as the applicant organization, though non-U.S. components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement, which can matter for projects involving overseas cohorts, specialized assays, or unique resources not available domestically.
Conceptually, the strongest applications for this FOA would be those that clearly center on mechanism: how HIV infection itself, persistent immune activation, viral reservoirs, co-infections, endothelial dysfunction, chronic inflammation, or ART-associated metabolic and inflammatory changes translate into specific heart, lung, or blood pathology. The announcement is also explicit about relevance to both adults and children, which opens the door to developmental and pediatric-specific mechanisms, differences in immune maturation, lifetime exposure to ART, and early-life determinants of cardiopulmonary or hematologic risk in perinatally infected populations. The deliverable NIH is looking for is not simply a descriptive association but a set of experimentally supported insights that explain disease processes well enough to point toward new therapeutic targets or more rational therapeutic design.
For applicants needing the full original text and application instructions, the FOA points to the NIH Grants Guide page (http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-024.html). For technical issues accessing the announcement or troubleshooting links, the contact listed is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: NIH RFA-HL-14-024 - Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)
What is the funding opportunity number and title?
The funding opportunity is NIH RFA-HL-14-024, titled "Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)."
What is the main purpose of this FOA?
The FOA supports investigator-initiated basic science projects focused on understanding why and how HIV contributes to diseases of the heart, lungs, and blood. The emphasis is on fundamental mechanisms of pathogenesis, with the goal of building a mechanistic foundation that can later inform smarter therapeutic strategies for HIV-associated HLB conditions.
What type of research is this FOA primarily looking for?
This FOA is centered on mechanistic, hypothesis-driven basic research. Applicants are expected to investigate underlying biology and causal pathways rather than primarily testing a clinical intervention or conducting a population-level outcomes study.
Does the FOA support research in both adults and children?
Yes. The announcement explicitly covers HIV-related heart, lung, and blood diseases in both adults and children, allowing for studies that address pediatric and developmental mechanisms as well as adult disease processes.
Are studies in the antiretroviral therapy (ART) era allowed?
Yes. The FOA explicitly welcomes studies of HIV-related HLB disease both in the absence of ART and in the modern ART treatment era, recognizing that ART has reshaped HIV biology and risk profiles while not eliminating cardiovascular, pulmonary, and hematologic complications.
What grant mechanism is used for this opportunity?
The FOA uses the NIH R01 research project grant mechanism, which is NIH's standard mechanism for hypothesis-driven, multi-year research programs led by a principal investigator.
What kinds of experimental systems or approaches are encouraged?
The FOA allows a wide range of experimental systems and approaches, including studies using primary cell types, patient-derived biospecimens, computational approaches, and other modeling strategies.
Are animal models encouraged?
Yes. The announcement emphasizes the use of animal models, particularly those commonly used in HIV research, reflecting interest in controlled mechanistic studies that can connect viral factors, host responses, and treatment-related effects.
What scientific areas within heart, lung, and blood are within scope?
The scope is broad across heart, lung, and blood domains, with examples consistent with molecular and cellular studies of inflammation and immune dysregulation affecting vascular or lung tissue, systems-level modeling of pathways related to ART-era cardiopulmonary risk, and mechanistic hematology studies involving coagulation, platelet function, anemia, or bone marrow effects in chronic HIV infection and treatment.
What is the overall deliverable NIH is looking for from funded projects?
The FOA is seeking experimentally supported mechanistic insights that explain disease processes, not just descriptive associations. The intent is to identify mechanisms well enough to suggest new therapeutic targets or support more rational therapeutic design later on.
Is sleep-related research included in the administrative scope?
The opportunity is aligned with multiple CFDA listings, including 93.233 (National Center on Sleep Disorders Research), which suggests applications may intersect with related physiological systems when relevant to HIV-associated HLB disease mechanisms.
Which CFDA listings are associated with this FOA?
The FOA is aligned with CFDA 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), 93.839 (Blood Diseases and Resources Research), and 93.233 (National Center on Sleep Disorders Research).
Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching.
What is the published award ceiling?
The published award ceiling is listed as $499,999, which sets expectations about the likely scale of direct costs considered under this announcement (while applicants would still need to follow NIH budget rules and applicable policy details in the full FOA).
When was this FOA posted, and what were the key dates?
The FOA was posted on October 23, 2013. It had an original closing date of January 8, 2015, and a final closing date of January 8, 2016. It was archived on February 8, 2016.
Is this FOA still open for applications?
No. Based on the dates provided, the FOA was time-limited, reached its final closing date on January 8, 2016, and was archived on February 8, 2016.
What types of organizations are eligible to apply?
Eligibility is broad across public and private sectors. Eligible applicants include state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses; for-profit organizations other than small businesses; independent school districts; public housing authorities/Indian housing authorities; and various institution types identified in NIH policy such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISIs. The FOA also notes that certain federal agencies and faith-based or community-based organizations may be eligible.
Are foreign (non-U.S.) institutions eligible to apply as the applicant organization?
No. Non-U.S. entities (foreign institutions) are not eligible to apply as the applicant organization under this FOA.
Can a U.S. applicant include foreign components in the project?
Yes. While foreign institutions cannot be the applicant organization, non-U.S. components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement.
What does the FOA suggest are strong conceptual themes for applications?
Strong applications would clearly center on mechanism, such as how HIV infection, persistent immune activation, viral reservoirs, co-infections, endothelial dysfunction, chronic inflammation, or ART-associated metabolic and inflammatory changes translate into specific heart, lung, or blood pathology.
Does the FOA encourage pediatric-specific or developmental mechanistic angles?
Yes. Because the FOA includes children, it opens the door to developmental and pediatric-specific mechanisms, including differences in immune maturation, lifetime exposure to ART, and early-life determinants of cardiopulmonary or hematologic risk in perinatally infected populations.
Where can applicants find the full original FOA text and instructions?
The FOA points to the NIH Grants Guide page: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-024.html
Who is the contact for technical issues accessing the announcement or troubleshooting links?
For technical issues, the FOA lists the NIH Office of Extramural Research webmaster: FBOWebmaster@OD.NIH.GOV
Browse more opportunities from the same category: Health
Next opportunity: Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21)
Previous opportunity: Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 14 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 14 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21) Apply for PAR 13 380 Funding Number: PAR 13 380 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) Apply for PAR 13 379 Funding Number: PAR 13 379 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Marquette, Michigan Omaha, Nebraska and Hood River, Oregon Apply for HRSA 14 108 Funding Number: HRSA 14 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Social and Behavioral Datasets in Aging (R03) Apply for RFA AG 14 008 Funding Number: RFA AG 14 008 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Clinical Research in the Prevention, Diagnosis, and Treatment of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 023 Funding Number: RFA HL 14 023 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01) Apply for RFA AI 13 055 Funding Number: RFA AI 13 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY14 Region 5 Ohio(Athens, Crawford, DelawareFranklin, Hocking, Lucas, Madison, Mahoning, Marion, Medina, Pickaway, Portage, Richland, Stark, Summit, Trumbull, Union and Wayne counties )Announcement of Anticipated Availability of Funds for Family Apply for PA FPH 14 033 Funding Number: PA FPH 14 033 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,924,926 |
| FY14 Region 6 Louisiana(entire state)Announcement of Anticipated Availability of Funds for Family Planning Services Grants Apply for PA FPH 14 034 Funding Number: PA FPH 14 034 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,745,826 |
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 14 006 Funding Number: HRSA 14 006 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season Apply for RFA IP 14 001 Funding Number: RFA IP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Affordable Care Act Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 14 060 Funding Number: HRSA 14 060 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Primary Care Services Resources Coordination and Development Apply for HRSA 14 001 Funding Number: HRSA 14 001 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood and Vascular Systems Response to Sepsis (R01) Apply for RFA HL 14 028 Funding Number: RFA HL 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| STD/HIV Disease Intervention Services Training Centers (DISTC) Apply for CDC RFA PS14 1408 Funding Number: CDC RFA PS14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 059 Funding Number: HRSA 14 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Replication of Key Clinical Trials Initiative (U01) Apply for PAR 13 383 Funding Number: PAR 13 383 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Evidence Base and Capacity for Implementing HIV Prevention and Care and Treatment Programs in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1403 Funding Number: CDC RFA GH14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 1405 Funding Number: CDC RFA PS14 1405 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) Apply for RFA AA 14 001 Funding Number: RFA AA 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25) Apply for PAR 13 384 Funding Number: PAR 13 384 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 14 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.